Journal of Dermatology for Physician Assistants
The official journal of the Society of Dermatology Physician Assistants
Menu
The official journal of the Society of Dermatology Physician Assistants
ABOUT: Published quarterly in both print and interactive digital formats, JDPA covers a variety of topics in Clinical, Surgical, & Cosmetic Dermatology.
EDITORIAL MISSION: The mission of the JDPA is to improve dermatological patient care by publishing the most innovative, timely, practice-proven educational information available for the physician assistant profession.
SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 1. Efficacy and Safety of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a Phase
SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 3. Long-term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis in a
SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 4. Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey
SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 42. Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry Analysis Click here to download
SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 39. Deucravacitinib Long-term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3
SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 40. Bimekizumab (BKZ) Efficacy in High-impact Areas for Patients (pts) with Moderate to Severe Plaque Psoriasis:
SDPA Presents 20th Annual Fall Dermatology Conference–Abstracts and Posters November 16-20, 2022, Miami, FL 41. Deucravacitinib Significantly Improves Symptoms and Signs of Psoriasis in Patients With Moderate to Severe Psoriasis: